Coherus BioSciences today announced positive topline results for the first of 3 pharmacokinetic bioequivalence studies comparing CHS-1420, an adalimumab biosimilar candidate, and European-sourced reference Humira.
Coherus BioSciences today announced positive topline results for the first of 3 pharmacokinetic bioequivalence studies comparing CHS-1420, an adalimumab biosimilar candidate, and European-sourced reference Humira.
The California-based biosimilar developer said that the study (a randomized, single-blind, single-dose, parallel-group study in 216 healthy subjects) met its 3 primary endpoints: maximum serum concentration, area under the time-concentration curve from first to last time point measured, and area under the time-concentration curve from first time point extrapolated to infinity. The 90% confidence intervals of the geometric mean ratios for all PK endpoints fell within predefined bioequivalence boundaries of 80% to 125%.
News of Coherus’ results comes just days after the FDA approved another adalimumab biosimilar, Boehringer Ingelheim’s (BI) Cyltezo, for multiple indications. BI is also currently investigating interchangeability between its product and Humira.
However, while AbbVie faces mounting competition for its top-selling treatment, it is unlikely that the drug maker will see immediate erosion of its sales in the US marketplace; earlier this month, AbbVie filed suit against BI, claiming that the biosimilar developer will infringe on 74 of its patents covering Humira. With only 8 of those patents currently being litigated, the case could take a substantial period of time and investment of resources to resolve.
Likewise, the first US-approved adalimumab biosimilar, Amgen’s Amjevita, is still awaiting its launch after receiving the FDA’s approval in September of 2016. Litigation in AbbVie v Amgen is ongoing, with the case recently reassigned to a visiting judge in the Eastern District of Pennsylvania.
AbbVie faces a harder fight to protect its Humira sales in the international marketplace, however. In Australia, a federal court recently ruled that AbbVie cannot file for an extension of 3 of its patents on Humira because they protect methods of use rather than the drug itself.
Meanwhile, Samsung Bioepis’ own adalimumab biosimilar, Imraldi, was approved in the European Union last week after having received a previous positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use in June of 2017.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: EU Biosimilar Approval, Launches and Product Returns, Denosumab Switching Data
July 10th 2024The European Union approves a tocilizumab biosimilar and the US sees another launch, Genentech’s ophthalmology biobetter returns to the market, and Samsung Bioepis shares data on switching to its denosumab biosimilar.